Systemic treatment patterns and adherence to guidelines in Japanese patients with metastatic non-small cell lung cancer
- 28 February 2025
- journal article
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (9) , 1101-1111
Abstract
Non-small-cell-lung cancer (NSCLC) medication use and guideline adherence remain unclear. We investigated treatment patterns and adherence among Japanese patients with NSCLC. We analyzed treatment patterns and guideline adherence by age and histology in ≥ 20-year-olds with stage IV NSCLC treated between 2016-2018 using diagnostic procedure combination data. Logistic regression analysis evaluated the impact of various factors on guideline adherence. We included 9,722 patients. In < 75-year-olds with nonsquamous NSCLC, first-to third-line treatments comprised 31.8% platinum combination therapy, 26.3% immune checkpoint inhibitors, and 62.5% cytotoxic chemotherapy. In ≥ 75-year-olds, first-line and second-line molecular targeted therapies represented 46.6% and 35.6%, whereas third-line cytotoxic chemotherapy represented 42.3%. In squamous NSCLC, first-line platinum combination therapy was predominant (69.7% and 47.7% for < 75-and ≥75-year-olds). The most common second-line and third-line therapies were immune checkpoint inhibitors (48.6% and 50.8% for < 75-and ≥75-year-olds) and cytotoxic chemotherapy (62.5% and 55.2% for < 75-and ≥75-year-olds), respectively. The highest guideline adherence (90%) was in < 75-year-olds with squamous NSCLC. Age, histology, activities of daily living, and cumulative hospitalizations over the past 18 months influenced treatment adherence. New NSCLC drug introduction increased regardless of age, suggesting prognosis improvement. More efficient drug application and broader guideline dissemination are required.Keywords
Funding Information
- Ministry of Health and Labour Welfare
- Graduate School of Medicine of the International University of Health and Welfare
This publication has 21 references indexed in Scilit:
- Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patientsLung Cancer, 2022
- Lung Cancer in JapanJournal of Thoracic Oncology, 2022
- Association between hospital volume and mortality of patients with metastatic non-small cell lung cancerLung Cancer, 2018
- Systemic Treatment Patterns With Advanced or Recurrent Non–small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database StudyClinical Therapeutics, 2017
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Guideline-concordant lung cancer care and associated health outcomes among elderly patients in the United StatesJournal of Geriatric Oncology, 2015
- Guideline‐concordant cancer care and survival among American Indian/Alaskan Native patientsCancer, 2014
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007